VL-0395

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532878

CAS#: 620167-11-5

Description: VL-0395 is a CCK1 receptor antagonist.


Chemical Structure

img
VL-0395
CAS# 620167-11-5

Theoretical Analysis

MedKoo Cat#: 532878
Name: VL-0395
CAS#: 620167-11-5
Chemical Formula: C26H23N5O4
Exact Mass: 469.18
Molecular Weight: 469.500
Elemental Analysis: C, 66.51; H, 4.94; N, 14.92; O, 13.63

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: VL-0395, VL 0395, VL0395

IUPAC/Chemical Name: 3-[[3-[(5-carbamimidoyl1H-indole-2-carbonyl)amino]benzoyl]amino]-3-phenylpropanoic acid

InChi Key: RVWSCZNGPOUASU-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H23N5O4/c27-24(28)16-9-10-20-18(11-16)13-22(30-20)26(35)29-19-8-4-7-17(12-19)25(34)31-21(14-23(32)33)15-5-2-1-3-6-15/h1-13,21,30H,14H2,(H3,27,28)(H,29,35)(H,31,34)(H,32,33)

SMILES Code: O=C(O)CC(NC(C1=CC=CC(NC(C(N2)=CC3=C2C=CC(C(N)=N)=C3)=O)=C1)=O)C4=CC=CC=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 469.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Pavan MV, Lassiani L, Berti F, Stefancich G, Ciogli A, Gasparrini F, Mennuni L, Ferrari F, Escrieut C, Marco E, Makovec F, Fourmy D, Varnavas A. New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R). J Med Chem. 2011 Aug 25;54(16):5769-85. doi: 10.1021/jm200438b. Epub 2011 Jul 20. PubMed PMID: 21728335.

2: Lassiani L, Pavan MV, Berti F, Kokotos G, Markidis T, Mennuni L, Makovec F, Varnavas A. Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand. Bioorg Med Chem. 2009 Mar 15;17(6):2336-50. doi: 10.1016/j.bmc.2009.02.012. Epub 2009 Feb 14. PubMed PMID: 19261479.

3: Varnavas A, Lassiani L, Valenta V, Ciogli A, Gasparrini F, Mennuni L, Makovec F. N-terminal anthranoyl-phenylalanine derivatives as CCK1 receptor antagonists: the final approach. Med Chem. 2005 Sep;1(5):501-17. PubMed PMID: 16787335.

4: De Luca S, Saviano M, Lassiani L, Yannakopoulou K, Stefanidou P, Aloj L, Morelli G, Varnavas A. Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their "receptor desmodynamic processes". J Med Chem. 2006 Apr 20;49(8):2456-62. PubMed PMID: 16610788.

5: Varnavas A, Lassiani L, Valenta V, Mennuni L, Makovec F, Hadjipavlou-Litina D. Anthranilic acid based CCK1 receptor antagonists: preliminary investigation on their second "touch point". Eur J Med Chem. 2005 Jun;40(6):563-81. PubMed PMID: 15922840.

6: Varnavas A, Lassiani L, Valenta V, Berti F, Tontini A, Mennuni L, Makovec F. Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept. Eur J Med Chem. 2004 Jan;39(1):85-97. PubMed PMID: 14987837.

7: Varnavas A, Lassiani L, Valenta V, Berti F, Mennuni L, Makovec F. Anthranilic acid derivatives: a new class of non-peptide CCK1 receptor antagonists. Bioorg Med Chem. 2003 Mar 6;11(5):741-51. PubMed PMID: 12538004.